目的 探讨影响胆管细胞性肝癌外科治疗预后的因素.方法 回顾性分析2000年1月至2010年1月天津医科大学附属肿瘤医院行外科治疗的99例胆管细胞性肝癌患者的临床资料.所有患者行常规淋巴结清扫,清扫范围包括肝门及第12、13和8组淋巴结.根据肿瘤的大小、位置、数目及肝功能状况确定肝切除的范围.患者术后半年内每个月门诊复查,半年后每3个月复查1次,2年后每半年复查1次,对怀疑有复发或疾病进展者每月复查1次.对未能按时就诊的患者进行电话随访.随访时间截至患者死亡或2013年3月.生存分析采用Log-rank检验.经过单因素分析有统计学意义的变量进一步采用COX逐步回归模型进行预后多因素分析.结果 99例胆管细胞性肝癌患者中,40例行半肝切除术,27例行扩大半肝切除术,20例行肝段切除术,12例行半肝切除+楔形切除术.99例患者均获得随访,中位随访时间为33个月(21.1~44.9个月).患者术后1、3、5年的无复发生存率及总生存率分别为64.6%、29.2%、22.7%和78.8%、46.4%、30.3%.单因素分析结果表明:病毒性肝炎、术前CA19-9、TNM分期、淋巴结转移、微血管侵犯、结节数目和R0切除是影响患者无复发生存率的危险因素(Log-rank值=5.048,5.982,20.128,13.148,29.632,32.488,50.574,P<0.05);术前CA19-9、TNM分期、淋巴结转移、微血管侵犯、结节数目和R0切除是影响患者总生存率的危险因素(Log-rank值=4.302,17.267,11.756,23.840,36.411,47.126,P<0.05).进一步分析发现:TNM分期患者(Ⅰ期20例、Ⅱ期44例、Ⅲ期8例、Ⅳ期27例)中,各期患者的无复发生存时间和总生存时间比较,差异均有统计学意义(Log-rank值=20.128,17.267,P<0.05).Ⅰ期与Ⅲ、Ⅳ期和Ⅱ期与Ⅳ期患者无复发生存时间比较,差异有统计学意义(Log-rank值=10.807,19.368,6.347,P<0.05);Ⅰ期与Ⅱ、Ⅲ、Ⅳ期和Ⅱ期与Ⅳ期患者总生存时间比较,差异有统计学意义(Log-rank值=6.119,4.015,16.282,4.929,P<0.05);其余各期患者比较,差异无统计学意义(P>0.05).多因素分析结果表明:TNMⅢ期和Ⅳ期、微血管侵犯、多结节和R0切除是影响无复发生存时间独立危险因素(RR=1.413,3.073,2.737,3.916,95%可信区间:1.119 ~1.784,1.837 ~5.140,1.338 ~4.207,1.849 ~8.291,P<0.05);淋巴结转移、微血管侵犯、多结节和R0切除是影响总生存时间的独立危险因素(RR=2.025,2.948,0.327,3.494,95%可信区间:1.215 ~3.374,1.774 ~4.900,0.183 ~0.583,1.670 ~7.310,P<0.05).结论 TNMⅢ期和Ⅳ期、淋巴结转移、微血管侵犯、多结节、非R0切除导致胆管细胞性肝癌患者术后无复发生存时间和总生存时间明显缩短,是预后不良的主要影响因素.R0切除是改善胆管癌患者预后的最大希望.
目的 探討影響膽管細胞性肝癌外科治療預後的因素.方法 迴顧性分析2000年1月至2010年1月天津醫科大學附屬腫瘤醫院行外科治療的99例膽管細胞性肝癌患者的臨床資料.所有患者行常規淋巴結清掃,清掃範圍包括肝門及第12、13和8組淋巴結.根據腫瘤的大小、位置、數目及肝功能狀況確定肝切除的範圍.患者術後半年內每箇月門診複查,半年後每3箇月複查1次,2年後每半年複查1次,對懷疑有複髮或疾病進展者每月複查1次.對未能按時就診的患者進行電話隨訪.隨訪時間截至患者死亡或2013年3月.生存分析採用Log-rank檢驗.經過單因素分析有統計學意義的變量進一步採用COX逐步迴歸模型進行預後多因素分析.結果 99例膽管細胞性肝癌患者中,40例行半肝切除術,27例行擴大半肝切除術,20例行肝段切除術,12例行半肝切除+楔形切除術.99例患者均穫得隨訪,中位隨訪時間為33箇月(21.1~44.9箇月).患者術後1、3、5年的無複髮生存率及總生存率分彆為64.6%、29.2%、22.7%和78.8%、46.4%、30.3%.單因素分析結果錶明:病毒性肝炎、術前CA19-9、TNM分期、淋巴結轉移、微血管侵犯、結節數目和R0切除是影響患者無複髮生存率的危險因素(Log-rank值=5.048,5.982,20.128,13.148,29.632,32.488,50.574,P<0.05);術前CA19-9、TNM分期、淋巴結轉移、微血管侵犯、結節數目和R0切除是影響患者總生存率的危險因素(Log-rank值=4.302,17.267,11.756,23.840,36.411,47.126,P<0.05).進一步分析髮現:TNM分期患者(Ⅰ期20例、Ⅱ期44例、Ⅲ期8例、Ⅳ期27例)中,各期患者的無複髮生存時間和總生存時間比較,差異均有統計學意義(Log-rank值=20.128,17.267,P<0.05).Ⅰ期與Ⅲ、Ⅳ期和Ⅱ期與Ⅳ期患者無複髮生存時間比較,差異有統計學意義(Log-rank值=10.807,19.368,6.347,P<0.05);Ⅰ期與Ⅱ、Ⅲ、Ⅳ期和Ⅱ期與Ⅳ期患者總生存時間比較,差異有統計學意義(Log-rank值=6.119,4.015,16.282,4.929,P<0.05);其餘各期患者比較,差異無統計學意義(P>0.05).多因素分析結果錶明:TNMⅢ期和Ⅳ期、微血管侵犯、多結節和R0切除是影響無複髮生存時間獨立危險因素(RR=1.413,3.073,2.737,3.916,95%可信區間:1.119 ~1.784,1.837 ~5.140,1.338 ~4.207,1.849 ~8.291,P<0.05);淋巴結轉移、微血管侵犯、多結節和R0切除是影響總生存時間的獨立危險因素(RR=2.025,2.948,0.327,3.494,95%可信區間:1.215 ~3.374,1.774 ~4.900,0.183 ~0.583,1.670 ~7.310,P<0.05).結論 TNMⅢ期和Ⅳ期、淋巴結轉移、微血管侵犯、多結節、非R0切除導緻膽管細胞性肝癌患者術後無複髮生存時間和總生存時間明顯縮短,是預後不良的主要影響因素.R0切除是改善膽管癌患者預後的最大希望.
목적 탐토영향담관세포성간암외과치료예후적인소.방법 회고성분석2000년1월지2010년1월천진의과대학부속종류의원행외과치료적99례담관세포성간암환자적림상자료.소유환자행상규림파결청소,청소범위포괄간문급제12、13화8조림파결.근거종류적대소、위치、수목급간공능상황학정간절제적범위.환자술후반년내매개월문진복사,반년후매3개월복사1차,2년후매반년복사1차,대부의유복발혹질병진전자매월복사1차.대미능안시취진적환자진행전화수방.수방시간절지환자사망혹2013년3월.생존분석채용Log-rank검험.경과단인소분석유통계학의의적변량진일보채용COX축보회귀모형진행예후다인소분석.결과 99례담관세포성간암환자중,40례행반간절제술,27례행확대반간절제술,20례행간단절제술,12례행반간절제+설형절제술.99례환자균획득수방,중위수방시간위33개월(21.1~44.9개월).환자술후1、3、5년적무복발생존솔급총생존솔분별위64.6%、29.2%、22.7%화78.8%、46.4%、30.3%.단인소분석결과표명:병독성간염、술전CA19-9、TNM분기、림파결전이、미혈관침범、결절수목화R0절제시영향환자무복발생존솔적위험인소(Log-rank치=5.048,5.982,20.128,13.148,29.632,32.488,50.574,P<0.05);술전CA19-9、TNM분기、림파결전이、미혈관침범、결절수목화R0절제시영향환자총생존솔적위험인소(Log-rank치=4.302,17.267,11.756,23.840,36.411,47.126,P<0.05).진일보분석발현:TNM분기환자(Ⅰ기20례、Ⅱ기44례、Ⅲ기8례、Ⅳ기27례)중,각기환자적무복발생존시간화총생존시간비교,차이균유통계학의의(Log-rank치=20.128,17.267,P<0.05).Ⅰ기여Ⅲ、Ⅳ기화Ⅱ기여Ⅳ기환자무복발생존시간비교,차이유통계학의의(Log-rank치=10.807,19.368,6.347,P<0.05);Ⅰ기여Ⅱ、Ⅲ、Ⅳ기화Ⅱ기여Ⅳ기환자총생존시간비교,차이유통계학의의(Log-rank치=6.119,4.015,16.282,4.929,P<0.05);기여각기환자비교,차이무통계학의의(P>0.05).다인소분석결과표명:TNMⅢ기화Ⅳ기、미혈관침범、다결절화R0절제시영향무복발생존시간독립위험인소(RR=1.413,3.073,2.737,3.916,95%가신구간:1.119 ~1.784,1.837 ~5.140,1.338 ~4.207,1.849 ~8.291,P<0.05);림파결전이、미혈관침범、다결절화R0절제시영향총생존시간적독립위험인소(RR=2.025,2.948,0.327,3.494,95%가신구간:1.215 ~3.374,1.774 ~4.900,0.183 ~0.583,1.670 ~7.310,P<0.05).결론 TNMⅢ기화Ⅳ기、림파결전이、미혈관침범、다결절、비R0절제도치담관세포성간암환자술후무복발생존시간화총생존시간명현축단,시예후불량적주요영향인소.R0절제시개선담관암환자예후적최대희망.
Objective To identify the prognostic factors for patients with intrahepatic cholangiocarcinoma.Methods The clinical data of 99 patients with intrahepatic cholangiocarcinoma who received surgical treatment at the Cancer Hospital of Tianjin Medical University from January 2000 to January 2010 were analyzed retrospectively.Lymph nodes at the hepatic portal and group 12,13 and 8 lymph nodes were resected.The range of hepatectomy was decided according to the size,location,number of tumor and the hepatic function.Patients were followed up every month within the first 6 months after operation,every 3 months at 6 months later,and they were followed up every half year at 2 years later.Patients who were suspected as with tumor recurrence or progression were followed up every month.All the patients were followed up till death or March of 2013.The survival was analyzed using the Log-rank test,and multivariate analysis was done using the COX regression model.Results Forty patients received hemi-hepatectomy,27 received extended hemi-hepatectomy,20 received segmentectomy,and 12 received hemi-hepatectomy + wedge resection.All the patients were followed up and the median time of follow-up was 33 months (range 21.1-44.9 months).The 1-,3-,5-year recurrence-free survival rates and total survival rates of the 99 patients were 64.6%,29.2%,22.7% and 78.8%,46.4% and 30.3%,respectively.The results of univariate analysis showed that hepatitis B or C virus infection,preoperative CA19-9 level,TNM staging,lymph node metastasis,microvascular invasion,number of nodules and Ro resection were risk factors influencing the recurrence-free survival time (Log-rank value =5.048,5.982,20.128,13.148,29.632,32.488,50.574,P <0.05).The peroperative CA19-9 level,TNM staging,lymph node metastasis,microvascular invasion,number of nodules and R0 resection were risk factors influencing the total survival rate (Log-rank value =4.302,17.267,11.756,23.840,36.411,47.126,P <0.05).There were significant differences in the recurrence-free survival time and total survival time between patients in different TNM stages (20 patients in stage Ⅰ,44 in stage Ⅱ,8 in stage Ⅲ and 27 in stage Ⅳ) (Log-rank value =20.128,17.267,P <0.05).There were significant difference in the recurrence-free survival time between patients in stage Ⅰ and Ⅲ,patients in stage Ⅰ and Ⅳ,and between patients in stage Ⅱ and Ⅳ (Log-rank value =10.807,19.368,6.347,P < 0.05).There were significant difference in the total survival time between patients in stage Ⅰ and Ⅱ,patients in stage Ⅰ and Ⅲ,patients in stage Ⅰ and Ⅳ and between patients in stage Ⅱ and Ⅳ (Log-rank value =6.119,4.015,16.282,4.929,P<0.05).There was no significant difference in the survival time between patients in other TNM stages (P > 0.05).The results of multivariate analysis showed that TNM stage Ⅲ and Ⅳ,microvascular invasion,multiple nodules and R0 resection were independent risk factors influencing the recurrence-free survival time (RR =1.413,3.073,2.737,3.916,95% confidence interval:1.119-1.784,1.837-5.140,1.338-4.207,1.849-8.291,P<0.05) ; lymph node metastasis,microvascular invasion,multiple tumors and R0 resection were the independent risk factors influencing the total survival time (RR =2.025,2.948,0.327,3.494,95% confidence interval:1.215-3.374,1.774-4.900,0.183-0.583,1.670-7.310,P < 0.05).Conclusions TNM stage Ⅲ and Ⅳ,lymph node metastasis,microvascular invasion,multiple nodules,non-R0 resection shorten the recurrence-free survival time and total survival time of patients who received surgical resection for intrahepatic cholangiocarcinoma,and they are the main factors influencing the prognosis.R0 resection could improve the survival of patients with intrahepatic cholangiocarcinoma.